Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Howard A. Burris, Takuji Okusaka, Arndt Vogel, Myung Ah Lee, Hidenori Takahashi, В. В. Бредер, Jean‐Frédéric Blanc, Junhe Li, Melinda Bachini, Magdalena Żotkiewicz, Jayne Abraham, Nikunj Patel, Julie Wang, Muzammil Ali, Nana Rokutanda, Gordon Cohen, Do‐Youn Oh
Topics & Concepts
GemcitabineDurvalumabMedicinePlaceboInternal medicineCancerResponse Evaluation Criteria in Solid TumorsOncologySurgeryPhases of clinical researchClinical trialPathologyNivolumabAlternative medicineImmunotherapyCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersLiver Diseases and Immunity